Knight Therapeutics Inc., a leading Pan American (ex. EU) specialty pharmaceutical company, announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. for the marketing of AmBisome (liposomal amphotericin B) in Brazil. The agreement will enter into force as of 1st January 2021.
“We are pleased to continue this already established partnership and are very grateful to Gilead for the continued trust in the Knight team,” said Samira Sakhia, President and COO of Knight. Our Brazilian team launched AmBisome in Brazil over 20 years ago and we are excited to continue the great work we have done with patients and physicians ”.
"The signing of this new agreement extends the historic collaboration between Gilead and Grupo Biotoscana (" GBT ") and confirms Knight's assessment of the GBT acquisition," said Amal Khouri, vice president of business development at Knight.
“Gilead values the ongoing partnership with GBT to meet medical needs in Brazil,” said Ahmed Afifi, vice president and head of the Latin America region at Gilead Sciences. With this new agreement, we are pleased to continue our cooperation with the extended GBT / Knight team to enable Brazilian patients to benefit from AmBisome ”.
AmBisome (Liposomal Amphotericin B) is a sterile lyophilized, non-pyrogenic intravenous infusion of liposomal amphotericin B. This medicinal product is indicated for the treatment of serious deep mycotic infections and / or endemic and opportunistic systemic mycoses, for the treatment of fever of undetermined origin (FOI) in neutropenic patients for whom the FOI corresponds persistent fever, which does not respond to antibiotic therapy after 96 hours and which is very indicative of a systemic fungal infection, as the primary therapy for visceral leishmaniasis in immunocompetent patients. AmBisome is a registered trademark of Gilead Sciences, Inc. and is the subject of a license from Gilead and has been in the portfolio of Knight's Brazilian subsidiary for over twenty years. Knight's subsidiaries are responsible for the distribution and commercial activities of AmBisome in Brazil as well as Bolivia, Paraguay and Peru.